&lt;p&gt;Plasma Messenger RNAs Identified Through Bioinformatics Analysis are Novel, Non-Invasive Prostate Cancer Biomarkers&lt;/p&gt;

Wang, Rui; Wu, Yingzi; Jin, Yu; Yang, Guizhu; Hao, Yi; Xu, Bin

doi:10.2147/ott.s221276

Cited by 18 publications

(17 citation statements)

References 30 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PPP1R14B was significantly overexpressed in ovarian clear cell carcinoma (OCCC) and associated endometriosis ( Worley et al, 2015 ). A bioinformatics analysis showed that PPP1R14B was significantly overexpressed in plasma mRNAs in PCa (prostate cancer) patients, but the role of PPP1R14B in cancer was still unknown ( Wang et al, 2020 ). Recent studies also showed that PPP1R14B were highly expressed in tumor tissues and patients with high expression of PPP1R14B had poor survival rates ( Zhao et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

PPP1R14B Is a Prognostic and Immunological Biomarker in Pan-Cancer

Deng

Peng

Li³

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

Recent studies have shown that PPP1R14B was highly expressed in tumor tissues and patients with high expression of PPP1R14B had poor survival rates. However, the function and mechanisms of PPP1R14B in tumor progression remain ill defined. There was also lack of pan-cancer evidence for the relationship between PPP1R14B and various tumor types based on abundant clinical data. We used the TCGA project and GEO databases to perform pan-cancer analysis of PPP1R14B, including expression differences, correlations between expression levels and survival, genetic alteration, immune infiltration, and relevant cellular pathways, to investigate the functions and potential mechanisms of PPP1R14B in the pathogenesis or clinical prognosis of different cancers. Herein, we found that PPP1R14B was involved in the prognosis of pan-cancer and closely related to immune infiltration. Increased PPP1R14B expression correlated with poor prognosis and increased immune infiltration levels in myeloid-derived suppressor cells (MDSCs). Our studies suggest that PPP1R14B can be used as a prognostic biomarker for pan-cancer. Our findings may provide an antitumor strategy targeting PPP1R14B, including manipulation of tumor cell growth or the tumor microenvironment, especially myeloid-derived suppressor cell infiltration.

show abstract

Section: Introductionmentioning

confidence: 99%

PPP1R14B Is a Prognostic and Immunological Biomarker in Pan-Cancer

Deng

Peng

Li³

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Nevertheless, they are not the unique, non-invasive biomarkers being currently studied. Others, such as neutrophil-to-lymphocyte ratio [53], DLX1, PCA3, and DUOX1 mRNA plasma expressions [54] or a 14-genes' panel urine test including PMP22, GOLM1, LMTK2, EZH2, GSTP1, PCA3, VEGFA, CST3, PTEN, PIP5K1A, CDK1, TMPRSS2, ANXA3, and CCND1 [55], are some of the most updated research in PC non-invasive biomarkers. However, as previously mentioned by several authors, such as H.P.…”

Section: Discussionmentioning

confidence: 99%

Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

MiRNAs play a relevant role in PC (prostate cancer) by the regulation in the expression of several pathways’ AR (androgen receptor), cellular cycle, apoptosis, MET (mesenchymal epithelium transition), or metastasis. Here, we report the role of several miRNAs’ expression patterns, such as miR-miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, miR-592, miR-141, miR-375, and miR-130b, with relevance in processes like cell proliferation and MET. Using Trizol® extraction protocol and TaqMan™ specific probes for amplification, we performed miRNAs’ analysis of 159 PC fresh tissues and 60 plasmas from peripheral blood samples. We had clinical data from all samples including PSA, Gleason, TNM, and D’Amico risk. Moreover, a bioinformatic analysis in TCGA (The Cancer Genome Atlas) was included to analyze the effect of the most relevant miRNAs according to aggressiveness in an extensive cohort (n = 531). We found that miR-210-3p, miR-23c, miR-592, and miR-93-5p are the most suitable biomarkers for PC aggressiveness and diagnosis, respectively. In fact, according with our results, miR93-5p seems the most promising non-invasive biomarker for PC. To sum up, miR-210-3p, miR-23c, miR-592, and miR93-5p miRNAs are suggested to be potential biomarkers for PC risk stratification that could be included in non-invasive strategies such as liquid biopsy in precision medicine for PC management.

show abstract

“…Subsequently, PCA3 and DLX1 showed higher expression in PCa patients when compared to healthy individuals, while DUOX1 and GSTP1 showed lower expression in PCa patients. Diagnostic potential of PCA3, DLX1, DUOX1 and GSTP1 was additionally demonstrated with AUC values of 0.76, 0.82, 0.71 0.64, respectively[82]. Yet since the results refer to PCa patients in comparison to healthy individuals, appropriate disease matched controls need to be applied to demonstrate added value[82].…”

mentioning

confidence: 99%

“…Diagnostic potential of PCA3, DLX1, DUOX1 and GSTP1 was additionally demonstrated with AUC values of 0.76, 0.82, 0.71 0.64, respectively[82]. Yet since the results refer to PCa patients in comparison to healthy individuals, appropriate disease matched controls need to be applied to demonstrate added value[82].…”

mentioning

confidence: 99%